For decades, HF patients have limited effective therapeutic options and a poor prognosis.[1,3–5] The traditional neuroendocrine inhibitors, ACEis and ARBs, inhibit the activity of ACE, reduce the retention of water and sodium, suppresses bradykinin degradation, and relax the blood vessels. The gene discussed is KNG1; the disease is hydrops fetalis.